Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients
β Scribed by Alice Vajda; Laure Marignol; Ruth Foley; Thomas H. Lynch; Mark Lawler; Donal Hollywood
- Book ID
- 116395559
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 738 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0305-7372
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Background Geneβdirected enzyme prodrug therapy (GDEPT) based on the __E. coli__ enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically administered prodrug, fludar
## Abstract ## BACKGROUND. This pilot randomized controlled trial (RCT) examined the clinical effects of 2 complementary (CAM) therapies, relaxation response therapy (RRT) and Reiki therapy, in men being treated with external beam radiotherapy (EBRx) for prostate cancer. ## METHODS. Study partic
## Abstract Geneβdirected enzyme prodrug therapy based on the __E. coli__ purine nucleoside phosphorylase (PNP) gene produces efficient tumour cell killing. PNP converts adenosine analogs into toxic metabolites that diffuse across cell membranes to kill neighbouring untransduced cells (PNPβGDEPT).